Pacira BioSciences, Inc. Common Stock

Compare this stock

PCRX Stock Report Card

Today's performance

38%

Performance

Score:

10/100

PCRX returned -42.37% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

Score:

67/100

16 analysts offer 12-month price targets for PCRX. Together, they have an average target of 57.5, the most optimistic target put PCRX at 63 within 12-months and the most pessimistic has PCRX at 52.

Technicals

Score:

21/100

PCRX receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

Score:

10/100

PCRX has missed earnings 8 times in the last 20 quarters.

Profit

Score:

55/100

Out of the last 20 quarters, PCRX has had 12 profitable quarters and has increased their profits year over year on 8 of them.

Volatility

Score:

45/100

PCRX has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

Pacira BioSciences, Inc. Common Stock Summary

Nasdaq / PCRX

Healthcare

Drug Manufacturers - Specialty & Generic

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Power up your portfolio